[10] [11] Post-marketing surveillance and clinical trial data have not demonstrated an increased incidence of MTC in patients treated with semaglutide compared to control populations, though the FDA notes that human relevance remains unknown
Long-term injection of performance-enhancing substances can lead to heart failure that can occur rapidly with little warning, as documented in recent medical case studies of young bodybuilders
Stripe, the processor behind Zenotis payment system, prohibits: Online sales of GLP-1s like semaglutide and tirzepatide Compounded medication sales Telehealth consultations tied to prescriptions Cross-state or pharmacy-involved fulfillment workflows These restrictions mean that even compliant, well-structured clinics can be flagged or shut down once Stripe detects certain keywords, prescription products, or billing behavior
Not everyone is sold on GLP-1 activators or natural alternatives to popular weight-loss drugs
adults aged 35, 44 is approximately 22.4%, per CDC NHANES data, rising to 32.4% among those aged 45, 54 [4]